Trial
NCT03697551
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Breast Cancer
Intervention
Satoreotide trizoxetan
Why stopped
Recruitment challenges and not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-07